Top

Thrombosis Journal

Published in:

Open Access 01-12-2021 | Lung Cancer | Research

Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer

Authors: Wei Xiong, Yunfeng Zhao, He Du, Yanmin Wang, Mei Xu, Xuejun Guo

Published in: Thrombosis Journal | Issue 1/2021

Abstract

Background

Cancer-associated venous thromboembolism (VTE) is common in patients with primary lung cancer. It has been understudied which authoritative risk assessment score of cancer-associated VTE is optimal for the assessment of VTE development in hospitalized medical patients with lung cancer.

Methods

Patients with lung cancer who had undergone computed tomography pulmonary angiography (CTPA), compression ultrasonography (CUS) of lower and upper extremities, and/or planar ventilation/perfusion (V/Q) scan to confirm the presence or absence of VTE during a medical hospitalization were retrospectively reviewed. Based on the actual prevalence of VTE among all patients, the possibility of VTE were reassessed with the Khorana score, the PROTECHT score, the CONKO score, the ONKOTEV score, the COMPASS-CAT score, and the CATS/MICA score, to compare their assessment accuracy for VTE development.

Results

A total of 1263 patients with lung cancer were incorporated into the final analysis. With respect to assessment efficiency for VTE occurrence, the scores with adjusted agreement from highest to lowest were the ONKOTEV score (78.6%), the PROTECHT score (73.4%), the CONKO score (72.1%), the COMPASS-CAT score (71.7%), the Khorana score (70.9%), and the CATS/MICA score (60.3%). The ONKOTEV score had the highest Youden index which was 0.68, followed by the PROTECHT score (0.58), the COMPASS-CAT score (0.56), the CONKO score (0.55), the Khorana score (0.53), and the CATS/MICA score (0.23).

Conclusions

Among the Khorana score, the PROTECHT score, the CONKO score, the ONKOTEV score, the COMPASS-CAT score, and the CATS/MICA score which are approved by authoritative guidelines, the ONKOTEV score is optimal for the assessment of VTE development in hospitalized medical patients with lung cancer.

Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. NCCN guidelines insights: Cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Cancer Netw. 2018;16(11):1289–303. https://doi.org/10.6004/jnccn.2018.0084.CrossRef

Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–81. https://doi.org/10.1016/S1470-2045(19)30336-5.CrossRefPubMed

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with Cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. https://doi.org/10.1200/JCO.19.01461.CrossRefPubMed

Shimabukuro-Vornhagen A, Böll B, Kochanek M, Azoulay É, von Bergwelt-Baildon MS. Critical care of patients with cancer. CA Cancer J Clin. 2016;66(6):496–517. https://doi.org/10.3322/caac.21351.CrossRefPubMed

Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309–25. https://doi.org/10.3322/caac.21341.CrossRefPubMed

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.CrossRefPubMed

Bade BC, Dela Cruz CS. Lung Cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24. https://doi.org/10.1016/j.ccm.2019.10.001.CrossRefPubMed

Ay C, Ünal UK. Epidemiology and risk factors for venous thromboembolism in lung cancer. Curr Opin Oncol. 2016;28(2):145–9. https://doi.org/10.1097/CCO.0000000000000262.CrossRefPubMed

Huang H, Korn JR, Mallick R, Friedman M, Nichols C, Menzin J. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study. J Thromb Thrombolysis. 2012;34(4):446–56. https://doi.org/10.1007/s11239-012-0741-7.CrossRefPubMed

10.

Howlett J, Benzenine E, Cottenet J, Foucher P, Fagnoni P, Quantin C. Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study. BMC Cancer. 2020;20(1):461. https://doi.org/10.1186/s12885-020-06930-1.CrossRefPubMedPubMedCentral

11.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–7. https://doi.org/10.1182/blood-2007-10-116327.CrossRefPubMedPubMedCentral

12.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–82. https://doi.org/10.1182/blood-2010-02-270116.CrossRefPubMed

13.

Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291–2. https://doi.org/10.1007/s11739-012-0784-y.CrossRefPubMed

14.

Pelzer U, Sinn M, Stieler J, Riess H. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy. Dtsch Med Wochenschr. 2013;138(41):2084–8. https://doi.org/10.1055/s-0033-1349608.CrossRefPubMed

15.

Cella CA, Di Minno G, Carlomagno C, et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist. 2017;22(5):601–8. https://doi.org/10.1634/theoncologist.2016-0246.CrossRefPubMedPubMedCentral

16.

Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, el Shemmari S, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist. 2017;22(10):1222–31. https://doi.org/10.1634/theoncologist.2016-0414.CrossRefPubMedPubMedCentral

17.

Munoz Martin AJ, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118(8):1056–61. https://doi.org/10.1038/s41416-018-0027-8.CrossRefPubMedPubMedCentral

18.

Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018;5(7):e289–98. https://doi.org/10.1016/S2352-3026(18)30063-2.CrossRefPubMedPubMedCentral

19.

van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102(9):1494–501. https://doi.org/10.3324/haematol.2017.169060.CrossRefPubMedPubMedCentral

20.

Rupa-Matysek J, Lembicz M, Rogowska EK, Gil L, Komarnicki M, Batura-Gabryel H. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. Med Oncol. 2018;35(5):63. https://doi.org/10.1007/s12032-018-1120-9.CrossRefPubMedPubMedCentral

21.

Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405.CrossRefPubMed

22.

Xiong W, Du H, Xu M, et al. An authoritative algorithm most appropriate for the prediction of pulmonary embolism in patients with AECOPD. Respir Res. 2020;21(1):218. https://doi.org/10.1186/s12931-020-01483-0.CrossRefPubMedPubMedCentral

23.

Guo J, Deng QF, Xiong W, Pudasaini B, Yuan P, Liu JM, et al. Comparison among different presentations of venous thromboembolism because of lung cancer. Clin Respir J. 2019;13(9):574–82. https://doi.org/10.1111/crj.13060.CrossRefPubMed

24.

Xiong W, Zhao Y, Xu M, Guo J, Pudasaini B, Wu X, et al. The relationship between tumor markers and pulmonary embolism in lung cancer. Oncotarget. 2017;8(25):41412–21. https://doi.org/10.18632/oncotarget.17916.CrossRefPubMedPubMedCentral

25.

Chen W, Zhang Y, Yang Y, Zhai Z, Wang C. Prognostic significance of arterial and venous thrombosis in resected specimens for non-small cell lung cancer. Thromb Res. 2015;136(2):451–5. https://doi.org/10.1016/j.thromres.2015.06.014.CrossRefPubMed

26.

Deng C, Wu S, Zhang L, Yang M, Lin Q, Xie Q, et al. Role of monocyte tissue factor on patients with non-small cell lung cancer. Clin Respir J. 2018;12(3):1125–33. https://doi.org/10.1111/crj.12640.CrossRefPubMed

27.

Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, le MaÃ®tre AÃ©, et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada clinical trials group trials. Cancer. 2009;115(23):5516–25. https://doi.org/10.1002/cncr.24596.CrossRefPubMed

28.

Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016;14(9):1773–8. https://doi.org/10.1111/jth.13378.CrossRefPubMedPubMedCentral

29.

Dapkevičiūtė A, Daškevičiūtė A, Zablockis R, Kuzaitė A, Jonušienė G, Diktanas S, et al. Association between the Khorana score and pulmonary embolism risk in patients with advanced stage lung cancer. Clin Respir J. 2020;14(1):3–8. https://doi.org/10.1111/crj.13092.CrossRefPubMed

30.

Alexander M, Ball D, Solomon B, MacManus M, Manser R, Riedel B, et al. Dynamic thromboembolic risk modelling to target appropriate preventative strategies for patients with non-small cell lung Cancer. Cancers (Basel). 2019;11(1):50. https://doi.org/10.3390/cancers11010050.CrossRef

31.

Mellema WW, van der Hoek D, Postmus PE, Smit EF. Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer. 2014;86(1):73–7. https://doi.org/10.1016/j.lungcan.2014.07.017.CrossRefPubMed

32.

Dou F, Li H, Zhu M, Liang L, Zhang Y, Yi J, et al. Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer. Respir Res. 2018;19(1):88. https://doi.org/10.1186/s12931-018-0791-2.CrossRefPubMedPubMedCentral

33.

Spyropoulos AC, Eldredge JB, Anand LN, Zhang M, Qiu M, Nourabadi S, et al. External validation of a venous thromboembolic risk score for Cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model. Oncologist. 2020;25(7):e1083–90. https://doi.org/10.1634/theoncologist.2019-0482.CrossRefPubMedPubMedCentral

34.

Gerotziafas GT, Mahé I, Lefkou E, AboElnazar E, Abdel-Razeq H, Taher A, et al. Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer. Thromb Res. 2020;191(Suppl 1):S50–7. https://doi.org/10.1016/S0049-3848(20)30397-2.CrossRefPubMed

35.

Kearon C, de Wit K, Parpia S, Schulman S, Afilalo M, Hirsch A, et al. Diagnosis of pulmonary embolism with d-dimer adjusted to clinical probability. N Engl J Med. 2019;381(22):2125–34. https://doi.org/10.1056/NEJMoa1909159.CrossRefPubMed

36.

Khorana AA. Simplicity versus complexity: an existential dilemma as risk tools evolve. Lancet Haematol. 2018;5(7):e273–4. https://doi.org/10.1016/S2352-3026(18)30067-X.CrossRefPubMed

Title: Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer
Authors: Wei Xiong
Yunfeng Zhao
He Du
Yanmin Wang
Mei Xu
Xuejun Guo
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Lung Cancer
Cancer-Associated Venous Thrombosis
Lung Cancer
Lung Cancer
Published in: Thrombosis Journal / Issue 1/2021
Electronic ISSN: 1477-9560
DOI: https://doi.org/10.1186/s12959-021-00339-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms

Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia

Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: a systematic review and metanalysis

Prevalence, risk, and outcome of deep vein thrombosis in acute respiratory distress syndrome

Malignant tumor is the greatest risk factor for pulmonary embolism in hospitalized patients: a single-center study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials